Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 3/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.31 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15984911 | 1.00 | S1PR2 (0.34) | S1PR2S1PR1LTA4HALOX15MEN1 | |
| SCHEMBL21690029 | 1.00 | S1PR2 (0.34) | S1PR2S1PR1LTA4HALOX15MEN1 | |
| SCHEMBL289167 | 0.89 | ALOX15 (0.38) | S1PR2S1PR1ALOX15MEN1CYP1A2 | |
| SCHEMBL7250717 | 0.89 | ALOX15 (0.38) | S1PR2S1PR1ALOX15MEN1CYP1A2 | |
| SCHEMBL7250716 | 0.89 | ALOX15 (0.38) | S1PR2S1PR1ALOX15MEN1CYP1A2 | |
| SCHEMBL287680 | 0.87 | ALOX15 (0.40) | S1PR2S1PR1ALOX15MEN1CYP1A2 | |
| SCHEMBL27999717 | 0.87 | ALOX15 (0.40) | S1PR2S1PR1ALOX15MEN1CYP1A2 | |
| SCHEMBL4268944 | 0.84 | S1PR2 (0.36) | S1PR2S1PR1LTA4HCYP1A2ANPEP | |
| SCHEMBL5548230 | 0.83 | ENPEP (0.50) | S1PR2S1PR1MEN1CYP1A2KMT2A | |
| Arginine SCHEMBL136113 | 0.80 | OTC (0.48) | ALOX15MEN1CYP1A2KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| EP-2934563-B1 | ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND APPLICATIONS THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENT RESEARCH (IN) | 2020-07-08 | — | — | EP | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| EP-3436045-A1 | SYNTHETIC COMPOUND FOR IMPROVING EFFICIENCY OF TRANSFECTION | Klinikum der Universität München (DE) | 2019-02-06 | — | — | EP | disclosed |
| CN-109232716-A | The high penetrating power prodrugs composition of polypeptide and polypeptide related compound | 上海泰飞尔生化技术有限公司 | 2019-01-18 | — | — | CN | disclosed |
| CN-108084246-A | The high penetrating power prodrugs composition of polypeptide and polypeptide related compound | 上海泰飞尔生化技术有限公司 | 2018-05-29 | — | — | CN | disclosed |
| WO-2017167870-A1 | SYNTHETIC COMPOUND FOR IMPROVING EFFICIENCY OF TRANSFECTION | KLINIKUM DER UNIVERSITÄT MÜNCHEN (DE) | 2017-10-05 | — | — | WO | disclosed |
| EP-2934563-A1 | ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND APPLICATIONS THEREOF | Jawaharlal Nehru Centre for Advanced Scientific Research (IN) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014097178-A1 | ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND APPLICATIONS THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2014-06-26 | — | — | WO | disclosed |
| EP-2427475-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE-RELATED COMPOUNDS | Yu, Chongxi (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127640-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE-RELATED COMPOUNDS | TECHFIELDS BIOCHEM CO., LTD. (CN) | 2010-11-11 | — | — | WO | disclosed |
| WO-2007047680-A2 | INCREASING THE ACTIVITY OF RADICAL S-ADENOSYL METHIONINE (SAM) ENZYMES | CARGILL, INCORPORATED (US) | 2007-04-26 | — | — | WO | disclosed |
| US-4298725-A | CULTURING PSEUDOMONAS | TATE & LYLE LIMITED (GB) | 1981-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | S1PR2 3038/4885S1PR1 3194/4885LTA4H 2828/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | S1PR2 3038/4885S1PR1 3194/4885LTA4H 2828/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | S1PR2 3038/4885S1PR1 3194/4885LTA4H 2828/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | S1PR2 3038/4885S1PR1 3194/4885LTA4H 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.